Recent patient studies surrounding this compound, specifically the high-dose formulation referred to as ZPHC, suggest a impressive effect on weight reduction and linked chronic conditions . Scientists believe read more that this dual agonist , targeting both GLP-1 and GIP pathways , may represent a major advance in the treatment of excess weight an